Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. - Wikidata - awgldk - TriplyDB

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

http://www.wikidata.org/entity/Q33369909

about

Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report Bortezomib in patients with renal impairment.Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group Proteasome inhibitors in the treatment of multiple myeloma Drug induced interstitial lung disease.Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization The use of novel agents in the treatment of relapsed and refractory multiple myeloma Opposing effects of bortezomib-induced nuclear factor-κB inhibition on chemical lung carcinogenesis.Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma Bortezomib for multiple myeloma.Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling.The role of bortezomib in the treatment of lymphoma.Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.Proteasomal regulation of pulmonary fibrosis.Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.Pulmonary toxicities from targeted therapies: a review.Current status of DILD in molecular targeted therapies.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Breathless on bortezomib A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies.The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient.Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin.Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia.Bortezomib-induced pneumonitis during bortezomib retreatment in multiple myeloma.Fatal pulmonary toxicity due to carfilzomib (Kyprolis™).Bortezomib-induced bronchiolitis obliterans organizing pneumonia.Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis.Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation.In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis.Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity.Bortezomib alleviates experimental pulmonary arterial hypertension.Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma

P2860

Q21198810-CF2CADAA-B105-4CF6-8980-002FC81E8335 Q33396250-79A43BCB-5D30-484C-98E2-37F31FBDDE3B Q33415992-5C4D51CA-E6AF-49E6-A312-756579461AF8 Q34585047-155FBA7B-7C20-459D-B50F-F3B3842A1A67 Q34611676-A9169AF0-4AF5-43BB-B802-1202BA2CA373 Q34641494-BE667B97-738B-4243-B719-4BE4C6805F36 Q35051496-61169E0B-0937-4F92-86CA-B122203AC0D7 Q35097319-40B8F033-EF1E-4E52-ADEC-28F16F5735C5 Q35883572-4658363B-E5B5-4798-813D-57188AF7AB92 Q36347292-1F20B3D8-FD56-41CB-A5FD-EBB7605FEAF5 Q36521862-42D8AF0F-EA48-49BC-9D09-FDDE961FF043 Q36604807-702124A1-8387-47AD-BA83-50E102103B4D Q36640798-FDF68C54-2BEF-48BB-9F0E-6FF83821E190 Q36678523-E48CE8C3-6CB2-43F9-A1FA-10D1F6A502CD Q37024073-F2895187-BF8A-4AB4-9CDC-DAFD683FD112 Q37190474-1028B555-D947-42DF-88E6-CE8D20FCA39D Q37693531-38B5168C-C70F-4819-9FB9-757D541F3E84 Q37842346-90534DEA-DC75-42E5-83FF-241970552B50 Q37955066-987DF8F6-775A-4F97-A57F-2CEC71D5A25B Q38059819-7896C7F6-5F24-4960-88EA-6A746DD8F04F Q38227506-D6FB676D-C81E-4CD1-A4CD-6AC2DAB78261 Q38231991-FDCECC91-F777-4AD9-AE1C-77B9FF35B6EA Q38246060-AC90A118-8EBD-419C-A161-840929A29102 Q38371059-E1F890F8-64E0-479E-984D-8B9920BA9113 Q38545052-8700F7D3-9FDF-4CD1-8107-6152FADBCFE0 Q39002810-3CFB370C-57F5-4052-9E4B-697723CAAB6F Q39980036-3FEB1C9E-25E2-4EBD-A6BA-C42DF9934A9D Q40025076-7E62E90B-1E51-4302-918E-A8D47B5B2D7E Q40254745-5163544C-7E33-4007-99E3-573F32E7EFF6 Q40285686-CB59BF2F-F8B2-4A17-B0B6-4A77187CA6C5 Q41184318-DA908BBA-1065-43E5-AE30-7F01CD8136CB Q41598573-CA0D0749-1023-4046-A8CA-E202F5FDB7CC Q42122199-E8CD1111-C3F4-46A6-BB87-E7FF559AAB62 Q42184785-8FB40C1F-FBC9-41A0-9389-2627B73DF51F Q46610850-A6231BF4-2F68-4399-8AFC-A74DE7CB817B Q47238436-C38F0BE4-558F-46B0-8D2D-087005B75D31 Q52335024-A5CF19B8-7F97-4173-88E5-26FE94832343 Q53154356-C7B9C2A2-E859-4F60-AFB2-825E1D46EFA0 Q57214849-E0F39F88-4C4A-4F74-A6EF-FF6C14D6F773

P2860

Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma.

http://www.wikidata.org/entity/Q33369909

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Severe pulmonary complications ...... r refractory multiple myeloma.

@ast

Severe pulmonary complications ...... r refractory multiple myeloma.

@en

type

label

Severe pulmonary complications ...... r refractory multiple myeloma.

@ast

Severe pulmonary complications ...... r refractory multiple myeloma.

@en

prefLabel

Severe pulmonary complications ...... r refractory multiple myeloma.

@ast

Severe pulmonary complications ...... r refractory multiple myeloma.

@en

P1433

Q33369909-38354AA0-1DAE-43ED-BC95-F988C598A622

P1476

Q33369909-2BB8BD19-7AF8-42EB-BF30-CC6145ADB3EF

P2093

Q33369909-1F900A7F-DCC2-4124-85DE-FFCDFCF1A176

Q33369909-4205FCA1-5F2B-4B2C-BB02-8A5A0FD4F8FA

Q33369909-6B5CD9D6-5FB9-446A-92B0-66B54E77BA3A

Q33369909-79FF3790-0B6F-4E44-8E3D-2544B724D085

Q33369909-8AD3252B-AC0E-42AF-AA9D-3CC49F6A7EBC

Q33369909-8B23EE22-8E39-4F6A-AA86-239AB3525647

Q33369909-B0CFFE89-8E3C-44EA-9793-627067362E8A

Q33369909-D088C6F2-C2B5-4257-8270-E27F5AE08338

Q33369909-D089A161-31EA-43D5-A92F-739A78A46F07

Q33369909-DF3C2952-CE6E-4B98-AFD4-FEFDE9A2E141

P304

Q33369909-86EFE547-DAF1-48CC-B667-511D139C039A

P31

Q33369909-15B39E2D-A418-442C-9B92-3C8C2C54917F

P356

Q33369909-D280426F-F09C-42EF-9033-1FB690BCAFC1

P407

Q33369909-ABF6C21C-109B-4525-A48E-401A687E7193

P433

Q33369909-2AF69A11-30D5-4F55-84DA-CF0E75B17121

P478

Q33369909-5D6A4540-D1FD-4F3C-B8C3-234A0D967387

P50

Q33369909-1EBD59CC-8145-4672-8E89-9659839F2FED

P577

Q33369909-ADBCF043-5694-4B5E-9571-4E0242574C62

P5875

Q33369909-29E34902-F8D0-4DA7-A11A-E531F3A59AA3

P698

Q33369909-FEC8B50E-817B-4FC2-9F77-6AA665E69B2B

P356

BLOOD-2005-11-4541

P1433

P1476

Severe pulmonary complications ...... r refractory multiple myeloma.

@en

P2093

Hiroto Narimatsu

http://www.w3.org/2001/XMLSchema#string

Kazuo Oshimi

http://www.w3.org/2001/XMLSchema#string

Keiya Ozawa

http://www.w3.org/2001/XMLSchema#string

Koichiro Yuji

http://www.w3.org/2001/XMLSchema#string

Makoto Sasaki

http://www.w3.org/2001/XMLSchema#string

Masaaki Takatoku

http://www.w3.org/2001/XMLSchema#string

Masahiro Kami

http://www.w3.org/2001/XMLSchema#string

Masateru Kawabata

http://www.w3.org/2001/XMLSchema#string

Shigesaburo Miyakoshi

http://www.w3.org/2001/XMLSchema#string

Shuichi Taniguchi

http://www.w3.org/2001/XMLSchema#string

P304

3492-3494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-11-4541

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7362586

http://www.w3.org/2001/XMLSchema#string

P698

16410442

http://www.w3.org/2001/XMLSchema#string